Nippon Shinyaku and the National Center of Neurology and Psychiatry jointly discovered the antisense oligonucleotide NS-051/NCNP-04. By omitting a portion of the dystrophin gene’s genetic material, NS-051/NCNP-04 creates a functioning dystrophin protein with a little shorter chain length, which should prevent the decline in muscle function.
With a strong sense of purpose, Nippon Shinyaku has been actively developing medications to cure uncommon and intractable diseases in order to quickly introduce solutions for DMD patients.
Read More: Clinical Trials for Duchenne (List of All Researches)
- Follow Us -
